Pay in 4 interest-free payments of $5.73 Learn more
Ships within 48 hours · Estimated delivery Oct 20 - Oct 25
The global oral thrombopoietin receptor agonists market was estimated at US$ 4.73 billion in 2023 and is projected to grow to US$ 9.95 billion by 2034, rising at a compound annual growth rate (CAGR) of 7% from 2024 to 2034
The drug met the primary and key secondary endpoints, delivering superior A1C reduction and On Monday, Novo Nordisk announced that the results from its Phase 3 trial investigating semaglutide as a treatment for Alzheimers did not confirm the superiority of semaglutide versus placebo in the reduction of progression, of the disease, according to the press release
Match the spend to the priority
Novo Nordisk advances early-stage obesity medication, amycretin, to phase 3 clinical development based on early-phase clinical trial results in people with obesity or excess weight, published in The Lancet
Chewing Technique: 1
US$ 29.08
US$ 25.80
US$ 21.58
